Lasersight
This article was originally published in The Gray Sheet
Executive Summary
Completes patent license agreement with a subsidiary of The Laser Center under which Lasersight is granted an exclusive license to U.S. patent 5,630,810. The patent relates to a "treatment method for preventing formation of central islands," a problem associated with laser refractive surgery performed with broad beam laser systems used to ablate corneal tissue, the firm says. Lasersight agrees to pay TLC 20% of the aggregate net royalties it receives from licensing of the TLC patent
You may also be interested in...
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.